Sign in

Eric Caldwell

Senior Research Analyst at Baird Financial Group, Inc.

Eric Coldwell is a Senior Research Analyst at Baird, specializing in Healthcare Supply Chain and Pharma Services with a particular focus on the Life Sciences Tools & Services and Healthcare Technology sectors. He covers prominent companies such as McKesson and has received significant recognition for his investment research, including being ranked by Thomson Reuters (StarMine) as the No. 1 stock picker in Life Sciences Tools & Services in 2016 and achieving a career success rate of 55% with an average return of 4.8% per rating, according to TipRanks data. Coldwell joined Baird in 2003 after previous positions as a senior analyst at Prudential Securities and Wachovia Securities; he holds a BA in Political Science from Wake Forest University and an MBA in Finance from Queens University, and is a three-time recipient of The Wall Street Journal's 'Best on the Street' designation.

Eric Caldwell's questions to QUEST DIAGNOSTICS (DGX) leadership

Question · Q3 2025

Eric Caldwell asked for clarification on the margin profile's moving pieces in Q3 and Q4, specifically sizing Project Nova and other investments relative to last year or original expectations, and their potential impact into 2026.

Answer

CFO Sam Samad stated that initial investment spend for the year was roughly $30 million ($10 million for LDT regs/QARA, $20 million for Project Nova). Most of the QARA spend occurred, but a significant portion of the $20 million for Nova was pushed to Q4 due to timing, not impacting 2026 negatively. He reiterated the 6-7 year implementation of Nova, with an expected total investment of $250-$310 million (OpEx and CapEx), consistent with prior guidance. He emphasized the ability to control the pace of these investments based on PAMA and macro conditions.

Ask follow-up questions

Question · Q3 2025

Eric Caldwell asked for clarification on the magnitude of Project Nova and other investment impacts on the Q4 margin profile, including any slippage from Q3, and how these investments might play out year-over-year in 2026 compared to original expectations.

Answer

CFO Sam Samad explained that initial investment spend for the year was roughly $30 million ($10 million for LDT regs, $20 million for Project Nova). Most of the LDT regs spend occurred, but a significant portion of the $20 million for Nova was pushed into Q4 due to timing, without a negative bleed-over effect into 2026. He reiterated the 6-7 year, $250-$310 million total investment for Nova (OpEx and CapEx) is consistent with prior expectations, and the pace of these investments can be controlled based on business headwinds like PAMA.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts